Search Result

Results for "

MCF-7 and MDA-MB-231

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (3) Apoptosis (32) Aurora Kinase (1) Bacterial (1) Bcl-2 Family (8) c-Myc (1) Carbonic Anhydrase (3) Caspase (4) CDK (5) Cytochrome P450 (2) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (1) Drug Derivative (4) E3 Ligase Ligand-Linker Conjugates (1) EGFR (7) Endogenous Metabolite (1) Epigenetic Reader Domain (1) ERK (1) Estrogen Receptor/ERR (2) Ferroptosis (1) FGFR (1) Fungal (1) Galectin (1) HDAC (2) Histone Demethylase (1) Histone Methyltransferase (2) HSP (2) JNK (1) Ligands for E3 Ligase (1) MDM-2/p53 (1) Melatonin Receptor (1) Mitochondrial Metabolism (1) Mixed Lineage Kinase (1) MMP (1) Necroptosis (3) NF-κB (2) NO Synthase (1) Nuclear Hormone Receptor 4A/NR4A (1) Oxysterol-binding Protein-related Protein (ORP) (1) P-glycoprotein (1) p38 MAPK (2) PARP (2) PDGFR (1) PERK (1) Photosensitizer (1) PI3K (4) PKC (2) PPAR (1) PROTACs (3) Raf (1) Ras (1) Reactive Oxygen Species (ROS) (3) Reference Standards (1) RIP kinase (1) Ser/Thr Kinase (1) Serotonin Transporter (1) Src (2) STAT (2) Survivin (1) Topoisomerase (6) Transmembrane Glycoprotein (1) Tyrosinase (2) VEGFR (5)
By Research Areas:	Cancer (69) Cardiovascular Disease (1) Endocrinology (3) Infection (3) Inflammation/Immunology (1) Neurological Disease (1)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Polymers (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1029

Danazol 4 Publications Verification	PKC Apoptosis Tyrosinase	Endocrinology Cancer
Danazol inhibits the proliferation of cancer cell MDA-MB-231 and MCF-7 with IC₅₀ of 65 µg/mL and 31 µg/mL. Danazol arrests the cell cycle at G1 phase, induces apoptosis in MDA-MB-231 through PKCα signaling pathway .

HY-126437

Poly-L-lysine hydrobromide (MW 30000-70000) 1 Publications Verification	Apoptosis Bcl-2 Family MDM-2/p53 VEGFR	Cardiovascular Disease Cancer
Poly-L-lysine hydrobromide (MW 30000-70000) is a water-soluble synthetic polypeptide. Poly-L-lysine hydrobromide (MW 30000-70000) downregulates Bcl-2 and upregulates Bax and p53 proteins. Poly-L-lysine hydrobromide (MW 30000-70000) promotes Apoptosis and reduces VEGF expression. Poly-L-lysine hydrobromide (MW 30000-70000) shows anticancer activity against a variety of tumors. Poly-L-lysine hydrobromide (MW 30000-70000) can also be used as a coating material .

HY-112589

BRITE-338733	Bacterial	Infection Cancer
BRITE-338733 is an inhibitor of E. coli RecA ATPase activity (IC₅₀: 4.7 μM). BRITE-338733 also inhibits the ATP hydrolysis activity of RSC chromatin remodeling enzyme by binding to its ATP-binding pocket and DNA (IC₅₀: 0.316 μM). BRITE-338733 exhibits cytotoxicity against MCF-7 and MDA-MB-231 breast cancer cells. BRITE-338733 can be used in studies on antibacterial adjuvants and anticancer research .

HY-N6990

Anhydrosecoisolariciresinol	Others	Cancer
Anhydrosecoisolariciresinol is from the flower of Wedelia biflora, has anti-tumor activities . Anhydrosecoisolariciresinol decreases the growth of human breast cancer MCF-7 and MDA-MB-231 cell lines .

HY-N8146

Bruceantinol	STAT Bcl-2 Family Ser/Thr Kinase Survivin c-Myc Apoptosis Necroptosis CDK	Infection Cancer
Bruceantinol is a quassinoid that can be isolated from Brucea javanica, inhibits pepper mottle virus (PepMoV) in pepper. Bruceantinol is a STAT3 inhibitor demonstrating potent antitumor activity in in vitro and in vivo human colorectal cancer (CRC) models. Bruceantinol has potent anti-leukemic activity. Bruceantinol strongly inhibits STAT3 DNA-binding ability (IC₅₀ = 2.4 pM), blocks the constitutive and IL-6-induced STAT3 activation, and suppresses transcription of MCL-1, PTTG1, survivin and c-Myc. Bruceantinol binds with CDK2/4/6 to facilitate protein degradation through proteasome pathway. Bruceantinol can dose- and time-dependently reduces the cell growth, impede cell proliferation, disrupts the cell cycle, and induces necrosis in MCF-7 cells and apoptosis in MDA-MB-231 cells .

HY-120275

CYD-2-11	Bcl-2 Family Apoptosis	Cancer
CYD-2-11 is a selective Bax agonist with a K_i value of 34.1 nM. CYD-2-11 induces cell apoptosis and shows antiproliferative activity to breast cancer MDA-MB-231 and MCF-7 cell lines with IC₅₀ values of 3.22 and 3.81 μM, respectively. CYD-2-11 suppresses tumor growth in MDA-MB-231 tumor models. CYD-2-11 can be used for the research of breast and lung cancer .

HY-148368

CYD-4-61	Bcl-2 Family Apoptosis	Cancer
CYD-4-61 is a novel Bax activator used for breast cancer research. CYD-4-61 inhibits triple-negative breast cancer MDA-MB-231 and ER-positive breast cancer MCF-7 cell lines proliferation. CYD-4-61 activates Bax protein to induce cytochrome c release and regulate apoptotic biomarkers, leading to cancer cell apoptosis .

HY-134008

Protoapigenone	Apoptosis Bcl-2 Family Caspase	Cancer
Protoapigenone is an antineoplastic agent isolated from ferns. Protoapigenone has significant inhibitory activity against Hep G2, Hep 3B, MCF-7, A549 and MDAMB-231, with IC₅₀s values of 1.60, 0.23, 0.78, 3.88 and 0.27 μg/mL respectively .

HY-15668

ST09	MMP Bcl-2 Family Caspase Apoptosis Drug Derivative	Cancer
ST09 is an efficient and low toxicity Curcumin (HY-N0005) derivative. ST09 significantly inhibits cell migration and downregulates the expression of MMP1, MMP2, and Vimentin. ST09 has strong cytotoxicity to breast cancer cells, such as MDA-MB-231, MCF7 and T47D cells. ST09 induces cell apoptosis by upregulating Bax and cleaved caspase-3/9. ST09 can be used in the research of cancer such as breast cancer .

HY-Z12208

N1-Phenylsuberamide	Drug Derivative	Cancer
N1-Phenylsuberamide is an organic amide compound, and its structure can be regarded as a simplified analogue of Vorinostat (HY-10221). N1-Phenylsuberamide exhibits moderate anti-proliferative activity against MDA-MB-231 and MCF-7 cells. N1-Phenylsuberamide does not show significant HDAC inhibitory activity and can only weakly induce the expression of the p21 gene. N1-Phenylsuberamide has extremely low relative binding affinity of estrogen receptor. N1-Phenylsuberamide can be used as a control compound .

HY-178955

EGFR-IN-182	EGFR HSP PI3K Caspase Apoptosis CDK ERK Akt	Cancer
EGFR-IN-182 (Compound 4) is an EGFR inhibitor with an IC₅₀ value of 199 nM. EGFR-IN-182 inhibits HSP90 and PI3K, with IC₅₀ values of 5.007 and 13.596 μM respectively. EGFR-IN-182 exhibits strong anti-proliferative activity against MCF-7 and MDA-MB-231 cells. EGFR-IN-182 downregulates Cyclin D1, inducing cell cycle arrest; it enhances the activity of caspase-9, inducing cell apoptosis. EGFR-IN-182 downregulates the expressions of ERK and AKT. EGFR-IN-182 can be used for research on breast cancer .

HY-161769

HL435	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
HL435 is a heterobifunctional molecule that degrades BRD4 by linking to JQ1, with DC₅₀ of 11.9 nM and 21.9 nM, in MDA-MB-231 and MCF-7 cells, respectively. HL435 inhibits the proliferation of MDA-MB-231, MCF-7, 22Rv1 and A549, arrests the cell cycle and induces apoptosis. HL435 exhibits antitumor activity in mouse model. (Pink: ligand for target protein JQ-1 (HY-78695); Black: linker (HY-W004640); blue: ligand for E3 ligase HL389 (HY-161770))

HY-157151

iPRMT1	Histone Methyltransferase	Cancer
iPRMT1 is a potent and selective PRMT1 inhibitor for breast cancer research. iPRMT1 inhibits breast cancer cell growth in vitro and in vivo with EC₅₀ values of 90, 70, and 9 nM in MCF7, T47D, and MDA-MB-231 cells, respectively .

HY-175269

MGB1Y	DNA Alkylator/Crosslinker DNA/RNA Synthesis Topoisomerase	Cancer
MGB1Y is a noncovalent DNA minor groove binder (MGB). MGB1Y potently inhibits cancer cells proliferation and topoisomerase I activity. MGB1Y downregulates their breast cancer-related genes in MCF7 and MDA-MB-231 cells. MGB1Y has a broad-spectrum anticancer activity, such as breast cancer, colon cancer, and leukemia .

HY-170955

HA-CD44 interaction inhibitor 3	Transmembrane Glycoprotein	Cancer
HA-CD44 interaction inhibitor 3 (compound 5d) is a Hyaluronic acid (HY-B0633A) (HA)-CD44 interaction inhibitor with antiproliferative activities. HA-CD44 interaction inhibitor 3 inhibits MDA-MB-231 (CD44++) cells and MCF-7 cells (CD44--) with EC₅₀s of 4.24 μM and 14.74 μM, respectively. HA-CD44 interaction inhibitor 3 shows the potential for cancer research .

HY-149636

Multi-target kinase inhibitor 2	EGFR CDK VEGFR Apoptosis	Cancer
Multi-target kinase inhibitor 2 is a multi-targeted kinase inhibitor, and exhibits activity against EGFR, Her2, VEGFR2, and CDK2 enzymes, with IC₅₀ values of 79 nM, 40 nM,136 nM, and 204 nM, respectively. Multi-target kinase inhibitor 2 shows cytotoxic effects were observed against HepG2, HeLa , MDA-MB-231 and MCF-7, with IC₅₀ of 41, 57, 51 and 59 μM. Multi-target kinase inhibitor 2 induces cell cycle arrest and apoptosis in HepG2 cells .

HY-161687

Cisplatin/Dasatinib prodrug-1	Src	Cancer
Cisplatin/Dasatinib prodrug-1 (Compound 3) is a prodrug of Cisplatin (HY-17394) and Dasatinib (HY-10181). Cisplatin/Dasatinib prodrug-1 exhibits antiproliferative activity against A2780, MDA-MB-231, MCF7, HCT116, RD, Thp1 and HL60 cancer cells with IC₅₀s of 0.1, 0.1, 0.36, 2.0, 0.4, 0.3 and 0.25 μM, respectively .

HY-B1029R

Danazol (Standard)	Reference Standards Tyrosinase PKC Apoptosis	Endocrinology Cancer
Danazol standard inhibits the proliferation of cancer cell MDA-MB-231 and MCF-7 with IC₅₀ of 65 µg/mL and 31 µg/mL. Danazol arrests the cell cycle at G1 phase, induces apoptosis in MDA-MB-231 through PKCα signaling pathway .

HY-171777

Erufosine ErPC3; Erucylphosphohomocholine	PI3K Akt Ras Raf p38 MAPK	Cancer
Erufosine is an inhibitor of PI3K/Akt and Ras/Raf/MAPK signaling pathways. Erufosine inhibits the activity of breast cancer cell lines MCF-7 and MDA-MB 231 (IC₅₀: 40.95/40.8 μM). Erufosine reduces the phosphorylation of PI3K (p85), Akt (PKB), and cRaf. Erufosine can be used in the study of breast cancer and myeloid leukemia .

HY-174232

EGFR/CA-IX-IN-1	EGFR Carbonic Anhydrase Caspase	Cancer
EGFR/CA-IX-IN-1 (Compound 14) is a dual inhibitor against epidermal growth factor receptor (EGFR) and carbonic anhydrase IX (CA-IX) with IC₅₀ values of 5.92 nM and 63 nM, respectively. EGFR/CA-IX-IN-1 shows strong cytotoxicity against breast cancer cells (MDA-MB-231, MCF-7) with IC₅₀ values of 5.78 μM and 8.05 μM, respectively. EGFR/CA-IX-IN-1 inhibits the catalytic activity of CA-IX, up-regulates BAX/Bcl-2, activates caspases, and arrests the cell cycle at the G1 phase. EGFR/CA-IX-IN-1 is promising for research of breast cancer .

HY-158388

Anticancer agent 215	Topoisomerase	Cancer
Anticancer agent 215 (1) is a Camptothecin compound, with IC₅₀ values of 5.2 nM and 8.2 nM in MCF-7 cells and MDA-MB-231 cells, respectively .

HY-158389

Anticancer agent 216	Topoisomerase	Cancer
Anticancer agent 216 (34A) is a Camptothecin compound, with IC₅₀ values of 9.6 nM and 11.6 nM in MCF-7 cells and MDA-MB-231 cells, respectively .

HY-158387

Anticancer agent 214	Topoisomerase	Cancer
Anticancer agent 214 (2) is a Camptothecin compound, with IC₅₀ values of 2.6 nM and 15.7 nM in MCF-7 cells and MDA-MB-231 cells, respectively .

HY-158390

Anticancer agent 217	Topoisomerase	Cancer
Anticancer agent 217 (35B) is a Camptothecin compound, with IC₅₀ values of 6.2 nM and 7.1 nM in MCF-7 cells and MDA-MB-231 cells, respectively .

HY-106159

SB-T-101141	Reactive Oxygen Species (ROS) p38 MAPK JNK PERK Ferroptosis	Cancer
SB-T-101141 is a novel taxane. SB-T-101141 effectively induces a noncanonical ferroptosis to overcome Paclitaxel (HY-B0015) resistance of breast cancer. SB-T-101141 facilitates the production of iron and ferrous ions and ROS. SB-T-101141 stably binds to KHSRP to inhibit the iron-dependent expression of CISD1 related to iron homeostasis. SB-T-101141 synergistically enhances the iron-dependent activation of JNK and PERK pathways via KHSRP. SB-T-101141 suppresses breast tumor growth in MCF-7(PR)/MDA-MB-231(PR) or KHSRP knock-down MCF-7 xenograft mice model .

HY-168720

Apoptosis inducer 32	Apoptosis	Cancer
Apoptosis inducer 32 (Compound 7g) is an apoptosis inducer with a K_D of 42 μM, showing anti-tumor activity. Apoptosis inducer 32 caused significant cellular morphological changes in MDA-MB-231 cells, including membrane bubbling, nuclear fragmentation, and apoptotic body formation. The IC₅₀ of Apoptosis inducer 32 in MCF-7, MDA-MB-231, and HEK cells is 4.77, 6.56 and 337.8 μM respectively .

HY-161868

DLC-50	PARP HDAC Apoptosis	Cancer
DLC-50 is a dual inhibitor for PARP-1 and HDAC-1 with IC₅₀ of 1.2 nM and 31 nM. DLC-50 inhibits the proliferation of cancer cells MDA-MB-436, MDA-MB-231, and MCF-7 with IC₅₀ of 0.3, 2.7 and 2.41 μM. DLC-50 induces apoptosis in MDA-MB-231, arrests the cell cycle at G2 phase .

HY-161995

FGFR1/VEGFR2-IN-2	Apoptosis Necroptosis FGFR VEGFR PDGFR	Cancer
FGFR1/VEGFR2-IN-2 (compound 6l) is a VEGFR2/FGFR1 dual inhibitor. The IC₅₀ values for VEGFR2 and FGFR1 are 0.025 µM and 0.026 µM respectively, and for EGFR and PDGFR-β, the IC₅₀ values are 0.106 µM and 0.077 µM. FGFR1/VEGFR2-IN-2 showes significant anti-cancer activity (GI=60.38%) on NCI-60 cell line, with an IC₅₀ of 8.51 µM in T-47D cell line and anti-migration. FGFR1/VEGFR2-IN-2 acts to arrest cells in the G1 phase and promote apoptosis and necrosis; the IC₅₀ for MCF-7 cell line exceeds 100 µM, and the IC₅₀ for MDA-MB-231 is 69.17 µM, non-toxic to normal cells .

HY-162751

Anticancer agent 249	HSP Apoptosis	Cancer
Anticancer agent 249 (Compound 89) is an inhibitor for Hsp90β with IC₅₀ of 16.5 μM in PC3MM2 cell. Anticancer agent 249 inhibits proliferation of cancer cells MCF-7, T47D, MDA-MB-231, MDA-MB-468 and SKBr3 with IC₅₀ of 1.8-5.3 μM. Anticancer agent 249 induces apoptosis in MDA-MB-231. Anticancer agent 249 exhibits antitumor efficacy in mice .

HY-173075

Anticancer agent 267	RIP kinase Mixed Lineage Kinase Necroptosis	Cancer
Anticancer agent 267 (Compound 5q) is the activator for RIPK3 and MLKL. Anticancer agent 267 inhibits the proliferation in a variety of cancer cell lines (IC₅₀ for MDA-MB-231, MDA-MB-486 and MCF-7 is 9.79, 10.77 and 5.94 μM, respectively), arrests cell cycle at subG1 phase, and induces necroptosis in cell MDA-MB-231. Anticancer agent 267 exhibits antitumor activity in mouse xenograft models .

HY-169408

EGFR-IN-137	Cytochrome P450 EGFR Apoptosis	Cancer
EGFR-IN-137 (Compound 4c) is an inhibitor for aromatase and EGFR with IC₅₀s of 1.67 μg/mL and 0.08 μg/mL. EGFR-IN-137 inhibits the proliferation of cancer cell MCF-7 and MDA-MB-231 with IC₅₀s of 1.62 µM and 4.14 µM. EGFR-IN-137 arrests the cell cycle at G0/G1 phase in MDA-MB-231, and induces apoptosis through caspase-dependent pathway .

HY-156378

Aurora A inhibitor 3	Aurora Kinase	Cancer
Aurora A inhibitor 3 (Compound 5h) inhibits Aurora-A kinase with an IC₅₀ value of 0.78 μM. Aurora A inhibitor 3 is cytotoxic, with GI₅₀ values of 0.12 μM and 0.63 μM for MCF-7 and MDA-MB-231 cells, respectively .

HY-161770

HL389	Ligands for E3 Ligase	Cancer
HL389 inhibits proliferation of cancer cells MDA-MB-231 and MCF-7, with IC₅₀ of 11.39 μM and 9.66 μM. HL389 can be utilized as the ligand for E3 ligase for the synthesis of PROTAC degrader HL435 (HY-161769) .

HY-144306

ERα degrader 4	Estrogen Receptor/ERR Apoptosis	Cancer
ERα degrader 4 is an excellent and selective estrogen receptor α (ERα) degrader (IC₅₀ of 0.31, 0.41 and 0.48 μM in MDA-MB-231, MCF-7 and MCF-7/ADR cells, respectively). ERα degrader 4 has potent inhibitory activity against MCF-7 cell lines. ERα degrader 4 is a potential SERDs candidate for the research of breast cancer .

HY-168901

Hck-IN-2	Src	Cancer
Hck-IN-2 (Compound 8e) is an HCK inhibitor. Hck-IN-2 is cytotoxic to tumor cells, with IC₅₀ values of 19.58 μM and 1.42 μM against MDA-MB231 and MCF-7, respectively. Hck-IN-2 has anti-tumor activity .

HY-155969

EGFR-IN-83	EGFR Apoptosis	Cancer
EGFR-IN-83 (Compound 9) is an EGFR inhibitor (IC₅₀: 2.53 nM). EGFR-IN-83 has antiproliferative activity against MCF-7 and MDA-MB-231 cells, with IC₅₀ of 2.50 μM and 1.96 μM. EGFR-IN-83 can induce cell apoptosis .

HY-152945

Antiproliferative agent-22	NF-κB	Cancer
Antiproliferative agent-22 (compound 2) is an anticancer agent. Antiproliferative agent-22 shoes anti-proliferative activities against MCF-7, MDA-MB-231 and MDA-MB-468 cells with IC₅₀ values of 6.2 μM, 3.3 μM and 3.3 μM, respectively .

HY-179062

Anticancer agent 280	Apoptosis	Cancer
Anticancer agent 280 (Compound 65) is an anti-cancer agent targeting triple-negative breast cancer (TNBC). Anticancer agent 280 exhibits IC₅₀ values of Anticancer agent 280 for MDA-MB-231, MDA-MB-231/LM2-4, Jurkat, and MCF-7 of 7.1, 11.65, 6.99, and 21.51 μM respectively. Anticancer agent 280 can cause significant arrest of cells in the S phase and induce cell apoptosis. Anticancer agent 280 can be used for the study of TNBC .

HY-N2741

Vitexin B-1	Bcl-2 Family	Cancer
Vitexin B-1 is an inhibitor of Bcl-2 and the agonist of Caspase. Vitexin B-1 has cytotoxic effect and induces apoptosis in MCF-7, ZR-75-1, MDA-MB-231, and COC1 cells with IC₅₀s of 3.2, 2.1, 1.8 and 0.39 μM, respectively .

HY-138210

N,O-Diacetyltyramine	Fungal	Infection
N,O-Diacetyltyramine is a compound with antibacterial activity and cytotoxicity that can be isolated from the actinomycete Pseudonocardia endophytica VUK-10. N,O-Diacetyltyramine has antibacterial activity against Gram-positive and Gram-negative bacteria and fungi. N,O-Diacetyltyramine is cytotoxic to MDA-MB-231, HeLa, MCF-7 and OAW-42 cells .

HY-159122

CA IX-IN-2	Carbonic Anhydrase Reactive Oxygen Species (ROS) Apoptosis	Cancer
CA IX-IN-2 (Compound 9o) is an inhibitor for carbonic anhydrase (CA), that inhibits CA IX, CA XII and CA II with an IC₅₀ of 5.6, 7.4 and 430 nM, respectively. CA IX-IN-2 inhibits the proliferation of cancer cell HCT-116, SW480, MDA-MB 231 and MCF-7, with IC₅₀s of 14.63-29.33 μM. CA IX-IN-2 intercalates DNA, arrests cell cycle at G1/S phase, and induces apoptosis in MDA-MB-231. CA IX-IN-2 affects the mitochondrial membrane potential (MMP), increases the intracellular ROS levels, causes mitochondrial damage, and inhibits the cell migration of MDA-MB-231. CA IX-IN-2 exhibits antitumor efficacy in mouse models .

HY-179070

Anticancer agent 281 TFA	Apoptosis	Cancer
Anticancer agent 280 TFA (Compound 65) is an anti-cancer agent targeting triple-negative breast cancer (TNBC). Anticancer agent 280 TFA exhibits IC₅₀ values of Anticancer agent 280 TFA for MDA-MB-231, MDA-MB-231/LM2-4, Jurkat, and MCF-7 of 7.1, 11.65, 6.99, and 21.51 μM respectively. Anticancer agent 280 TFA can cause significant arrest of cells in the S phase and induce cell apoptosis. Anticancer agent 280 TFA can be used for the study of TNBC .

HY-175173

EGFR-IN-166	EGFR	Cancer
EGFR-IN-166 (Compound 2) is a EGFR inhibitor. EGFR-IN-166 has potent anticancer activity against breast cancer cells with IC₅₀s of 69.63 and 22.84 μM for MCF-7 and MDA-MB-231 cells, respectively. EGFR-IN-166 significantly inhibits cell migration and EGFR expression. EGFR-IN-166 can be used for breast cancer research .

HY-116904

Anticancer agent 253	Apoptosis Akt	Cancer
Anticancer agent 253 (Compound 26) has anti-cancer activity against breast cancer cells, with IC₅₀s of 6 μM (MCF-7), 10 μM (MDA-MB-231) and 6.4 μM (4T1 cells). Anticancer agent 253 arrests cell cycle and induces mitochondria-mediated apoptosis in cancer cells. Anticancer agent 253 inhibits Akt phosphorylation in human breast and prostate cancer .

HY-161855

VEGFR-2-IN-50	VEGFR Apoptosis	Cancer
VEGFR-2-IN-50 (Compound 10f) is a VEGFR-2 inhibitor and apoptosis inducer, with an IC₅₀ value of 0.33 μM. VEGFR-2-IN-50 (Compound 10f) has growth inhibitory activity on MCF-7 and MDA-MB-231 breast cancer cell lines, with IC₅₀ values of 19.86 μM and 10.88 μM, respectively, which is expected to be used in the study of breast cancer diseases .

HY-146103

Antiproliferative agent-7	Apoptosis Reactive Oxygen Species (ROS)	Cancer
Antiproliferative agent-7 (compound 8f) is a potent anti-proliferative agent. Antiproliferative agent-7 has antiproliferative activity against cancer cell lines MCF-7, MDA-MB-231, HCT-116 and FR-2 with IC₅₀s of 3.5 μM, 15.54 μM, 30.43 μM and 34.8 μM, respectively. Antiproliferative agent-7 can increase ROS production and induce apoptosis .

HY-146452

Anticancer agent 57	Apoptosis	Cancer
Anticancer agent 57 (compound 14) potently inhibits MDA-MB-231, MDA-MB-468, and MCF-7 cell lines, with IC₅₀s of 6.43 ~ 8.00 μM. Anticancer agent 57 induces cell cycle arrest and significantly promotes apoptosis. Anticancer agent 57 inhibits tumor growth in nude mice xenografted with MADMB-231 cells. Anticancer agent 57 can be used for researching triple negative breast cancer (TNBC) .

HY-175638

Carbonic anhydrase-IN-35	Carbonic Anhydrase Apoptosis Bcl-2 Family CDK	Cancer
Carbonic anhydrase-IN-35 is a selective carbonic anhydrase (CA) inhibitor. Carbonic anhydrase-IN-35 potently inhibits tumor-associated hCA IX (K_i = 0.6 nM) and hCA XII (K_i = 2.2 nM). Carbonic anhydrase-IN-35 induces apoptosis in MCF-7 cells by elevating Bax, reducing Bcl-2, and downregulating CDK4/6. Carbonic anhydrase-IN-35 exhibits potent cytotoxicity against MCF-7 (IC₅₀ = 0.3975 μM normoxic/0.6575 μM hypoxic), MCF-7-ADR (IC₅₀> = 0.3975 μM normoxic/4.488 μM hypoxic), MDA-MB-231, and 4T1 breast cancer cells. Carbonic anhydrase-IN-35 can be used for the study of breast cancer .

HY-171477

Metahexestrol	Estrogen Receptor/ERR	Cancer
Metahexestrol is an estrogen receptor (E2R) inhibitor with antitumor activity. It significantly inhibits the proliferation of estrogen receptor-positive MCF-7 human breast cancer cells (ED₅₀ = 1.0 μM). Additionally, Metahexestrol also exhibits inhibitory effects in estrogen receptor-negative MDA-MB-231 cells, and its antiproliferative activity cannot be reversed by estrogen, suggesting that its mechanism of action may be partially independent of the E2R pathway. Metahexestrol can be used in research on estrogen-dependent breast cancer .

HY-N15636

Coccinine (-)-Coccinine	Serotonin Transporter P-glycoprotein	Neurological Disease Cancer
Coccinine ((-)-Coccinine) is a weak inhibitor of SERT (IC₅₀: 196.3 μM; K_i: 106.8 μM) and P-gp (IC₅₀: 0.96 mM). Coccinine exhibits significant anti-tumor activity against various cancer cell lines, such as breast cancer (MCF7, Hs578T, MDA-MB-231), colon cancer (HCT-15), and lung cancer (A549). Coccinine can be used in the research of tumors and neurological diseases .

Cat. No.	Product Name	Type

HY-126437

Poly-L-lysine hydrobromide (MW 30000-70000)

1 Publications Verification

Biochemical Assay Reagents

Poly-L-lysine hydrobromide (MW 30000-70000) is a water-soluble synthetic polypeptide. Poly-L-lysine hydrobromide (MW 30000-70000) downregulates Bcl-2 and upregulates Bax and p53 proteins. Poly-L-lysine hydrobromide (MW 30000-70000) promotes Apoptosis and reduces VEGF expression. Poly-L-lysine hydrobromide (MW 30000-70000) shows anticancer activity against a variety of tumors. Poly-L-lysine hydrobromide (MW 30000-70000) can also be used as a coating material .

Cat. No.	Product Name	Target	Research Area

HY-P10393

ERα17p ERα (295-311)	Apoptosis	Cancer
ERα17p (ERα 295-311) is the epitope of the CaM binding site on the estrogen receptor α (ER), which interacts with calmodulin (CaM) in a calcium-dependent manner. ERα17p regulates the migration of cancer cells MCF-7, SK-BR-3, T47D, and MDA-MB-231 through Rho/ROCK and PI3K/Akt signaling pathways. ERα17p inhibits proliferations of breast cancer cells, induces apoptosis, and inhibits tumor growth in mouse models .

HY-P10873

ST-CY14	Nuclear Hormone Receptor 4A/NR4A Mitochondrial Metabolism	Cancer
ST-CY14 is an inhibitor for Nur77-PPARγ interaction with an EC₅₀ of 3.15 μM, that binds to Nur77 (K_d=32 nM), blocks Nur77 from being ubiquitinated and degraded by PPARγ, reduces fatty acid uptake and mitochondrial respiration, and inhibits the transcription of CD36 and FABP4. ST-CY14 inhibits the proliferation and migration of cancer cell MCF7 and MDA-MB-231. ST-CY14 inhibits tumor growth and bone metastasis in mouse models .

Cat. No.	Product Name		Classification

HY-B1029

Danazol 4 Publications Verification		Alkynes
Danazol inhibits the proliferation of cancer cell MDA-MB-231 and MCF-7 with IC₅₀ of 65 µg/mL and 31 µg/mL. Danazol arrests the cell cycle at G1 phase, induces apoptosis in MDA-MB-231 through PKCα signaling pathway .

Cat. No.	Product Name		Classification

HY-126437

Poly-L-lysine hydrobromide (MW 30000-70000) 1 Publications Verification		Polymers
Poly-L-lysine hydrobromide (MW 30000-70000) is a water-soluble synthetic polypeptide. Poly-L-lysine hydrobromide (MW 30000-70000) downregulates Bcl-2 and upregulates Bax and p53 proteins. Poly-L-lysine hydrobromide (MW 30000-70000) promotes Apoptosis and reduces VEGF expression. Poly-L-lysine hydrobromide (MW 30000-70000) shows anticancer activity against a variety of tumors. Poly-L-lysine hydrobromide (MW 30000-70000) can also be used as a coating material .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

MCF-7 and MDA-MB-231

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Click Chemistry

Oligonucleotides

Natural
Products